CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $623,295 | -11.2% | 13,732 | +9.8% | 0.00% | -100.0% |
| Q2 2023 | $702,255 | +32.8% | 12,509 | +6.4% | 0.00% | – |
| Q1 2023 | $528,651 | +24.1% | 11,758 | +12.2% | 0.00% | – |
| Q4 2022 | $425,849 | -25.3% | 10,476 | +20.2% | 0.00% | -100.0% |
| Q3 2022 | $570,000 | -95.5% | 8,714 | -95.8% | 0.00% | -90.0% |
| Q2 2022 | $12,717,000 | -55.4% | 209,267 | -44.3% | 0.01% | -44.4% |
| Q4 2021 | $28,482,000 | -32.5% | 375,854 | -0.2% | 0.02% | -37.9% |
| Q3 2021 | $42,171,000 | -30.9% | 376,762 | -0.0% | 0.03% | -31.0% |
| Q2 2021 | $61,005,000 | +79.6% | 376,832 | +35.2% | 0.04% | +68.0% |
| Q1 2021 | $33,974,000 | -38.8% | 278,815 | -23.1% | 0.02% | -41.9% |
| Q4 2020 | $55,492,000 | -2.5% | 362,429 | -46.7% | 0.04% | -14.0% |
| Q3 2020 | $56,910,000 | +61.1% | 680,420 | +41.5% | 0.05% | +51.5% |
| Q2 2020 | $35,327,000 | +618.5% | 480,700 | +314.6% | 0.03% | +450.0% |
| Q1 2020 | $4,917,000 | – | 115,936 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |